Clinical trials · Texas
Lung cancer clinical trials in Texas
We’re tracking 312 recruiting lung cancer studies with a site in Texas — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT06043817RecruitingPhase 1/Phase 2
Study of STX-721 for advanced lung cancer with EGFR or HER2 changes
This trial tests a new drug, STX-721, for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR or HER2 exon 20 insertion). The study aims to see if the drug is safe and effective.
Houston, TexasAges 18 years+ - NCT06810544RecruitingPhase 1/Phase 2
Study of TNG456 for tumors with MTAP loss
This trial tests a new drug called TNG456, alone or with another drug (abemaciclib), for people whose tumors have lost the MTAP gene. It aims to see if the combination can shrink tumors or slow their growth.
Houston, TexasAges 18 years+ - NCT07181473RecruitingPhase 1
Safety of TJ101 for advanced solid tumors
This trial tests a new drug called TJ101 for people with advanced solid tumors who have tried standard treatments or have no standard options. It aims to see if the drug is safe and how well it works.
Houston, TexasAges 18 years+ - NCT03422302Recruiting
CPAP or breath-holding to reduce lung tumor motion
This study looks at whether using a CPAP breathing device or deep breath-holding can keep lung tumors from moving during targeted radiation. The goal is to improve safety and accuracy of stereotactic body radiation for lung cancer.
Houston, TexasAges 18 years+ - NCT07038343RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
San Antonio, TexasAges 18–75 - NCT06312137RecruitingPhase 3
Pembrolizumab with or without another drug for lung cancer after surgery
This trial tests adding a new drug (sacituzumab tirumotecan) to pembrolizumab for people with non-small cell lung cancer that did not completely disappear after initial treatment and surgery. The goal is to see if the combination works better than pembrolizumab alone.
Houston, TexasAges 18 years+ - NCT07100080RecruitingPhase 2/Phase 3
New drug vs chemotherapy for EGFR-mutated lung cancer
This trial tests a new drug called izalontamab brengitecan (BMS-986507) against standard chemotherapy (platinum plus pemetrexed) for people with a specific type of lung cancer that has an EGFR mutation and has stopped responding to newer targeted pills.
Houston, TexasAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
Houston, TexasAges 18 years+ - NCT06452277RecruitingPhase 3
Testing sevabertinib for advanced HER2-mutated lung cancer
This trial compares a new targeted drug called sevabertinib against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation. The goal is to see if sevabertinib works better and is safe.
Houston, TexasAges 18 years+ - NCT06841055RecruitingPhase 2
Pumitamig plus chemo for Stage IV lung cancer after immunotherapy
This trial tests a new investigational drug called Pumitamig (BNT327) given with chemotherapy for people with advanced non-small cell lung cancer (Stage IV) that has continued to grow after one prior treatment with immunotherapy and platinum chemotherapy. The study aims to see if this combination is safe and can help shrink the cancer.
Houston, TexasAges 18 years+ - NCT06170788RecruitingPhase 3
New Two-Drug Immunotherapy Combo vs. Standard Immunotherapy for Advanced Lung Cancer
This study compares a new combination of two immunotherapy drugs (sacituzumab tirumotecan plus pembrolizumab) versus pembrolizumab alone for people with advanced non-small cell lung cancer that has a high PD-L1 level (≥50%) and has not been treated yet. The goal is to see if the combination works better than the standard single immunotherapy.
Houston, TexasAges 18 years+ - NCT06345729RecruitingPhase 3
Study of Calderasib and Pembrolizumab for Advanced Lung Cancer
This trial tests a new combination of two drugs (Calderasib and Pembrolizumab) in people with a specific type of advanced lung cancer (non-small cell lung cancer) that has a KRAS G12C mutation and high PD-L1 levels. It aims to see if this treatment can help shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT05099172RecruitingPhase 1/Phase 2
Study drug for EGFR or HER2-mutated advanced lung cancer
This early-phase study tests a new investigational medicine (BAY2927088) in people with advanced non-small cell lung cancer (NSCLC) that has EGFR and/or HER2 mutations. It’s designed to see how the drug works and what side effects it causes, when standard options have not helped or aren’t suitable.
Houston, TexasAges 18 years+ - NCT04913311Recruiting
Testing markers to predict lung inflammation after lung cancer treatment
This study looks for early “predictive markers” to tell who is most likely to develop lung inflammation after standard treatment for non-small cell lung cancer. It may help clinicians spot problems sooner and tailor care, using additional monitoring during treatment.
Houston, TexasAges Any age - NCT02095808Recruiting
Testing blood and body markers in lung and chest cancers
This study looks at “biomarkers,” which are measurable signs in the body (often in blood or samples), in people with lung or other chest cancers. It may help researchers better understand these cancers and improve how they’re diagnosed or tracked.
Dallas, TexasAges 18 years+ - NCT06774963RecruitingPhase 1
Study of LNCB74 for advanced solid tumors
This trial tests a new drug called LNCB74 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective.
Houston, TexasAges 18 years+ - NCT07090499RecruitingPhase 1
Study of PF-08046876 for advanced solid tumors
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
Conroe, TexasAges 18 years+ - NCT05948865RecruitingPhase 1
Early trial drug for advanced solid tumors
This Phase 1 study tests CPO301 in adults with advanced or metastatic solid tumors that have worsened or cannot be treated with standard options. It aims to find the safest dose and understand how the treatment affects tumors, especially in certain lung cancer groups.
Dallas, TexasAges 18 years+ - NCT06545331RecruitingPhase 1
A study of XB010 for advanced solid tumors
This trial tests an investigational drug called XB010 for people with solid tumors that have spread or cannot be removed by surgery. It aims to see if XB010 is safe and effective for several cancer types, including lung, breast, head and neck, and esophageal cancers.
Austin, TexasAges 18 years+ - NCT07300150RecruitingPhase 1
PT0511 for KRAS-mutated or amplified advanced solid tumors
This trial tests a new drug called PT0511 that targets a specific gene change (KRAS) found in some advanced solid tumors. It's for people whose cancer has not responded well to other treatments and who are looking for a new option.
San Antonio, TexasAges 18 years+ - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Austin, TexasAges 18–99 - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Houston, TexasAges 18 years+ - NCT06618287RecruitingPhase 1/Phase 2
Testing BMS-986507 for advanced lung and breast cancers
This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.
Irving, TexasAges 18 years+ - NCT06586515RecruitingPhase 1
Testing a new drug for cancers with KRAS G12D mutation
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
San Antonio, TexasAges 18 years+
Lung cancer trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting lung cancer studies listed above.
- The University of Texas MD Anderson Cancer Center · 12 studies
- NEXT Oncology · 6 studies
- Oncology Consultants · 3 studies
- START San Antonio · 2 studies
- Avenzo Therapeutics
- Avenzo Therapeutics Recruiting Site
- Baylor University Medical Center
- Local Institution
What taking part in a lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Lung cancer trials in other states
Common questions
- Are there lung cancer clinical trials in Texas?
- Yes. We're currently tracking 312 recruiting lung cancer studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lung cancer study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lung cancer studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.